A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

October 29, 2027

Study Completion Date

October 18, 2028

Conditions
Lymphoma, Non-HodgkinRefractory B-Cell NHLRelapsed B-cell NHL
Interventions
DRUG

JNJ-88998377

JNJ-88998377 will be administered.

Trial Locations (19)

10043

RECRUITING

National Taiwan University Hospital, Taipei

33382

RECRUITING

Linkou Chang Gung Memorial Hospital, Taoyuan District

34010

RECRUITING

Koc University Medical Faculty, Istanbul

40138

RECRUITING

A O U Sant Orsola Malpighi, Bologna

100142

RECRUITING

Beijing Cancer Hospital, Beijing

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

300181

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310002

RECRUITING

The First Affiliated Hospital Zhejiang University College of Medicine, Hangzhou

510062

RECRUITING

Sun Yat Sen University Cancer Center, Guangzhou

104 0045

COMPLETED

National Cancer Center Hospital, Chūōku

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa

135 8550

RECRUITING

The Cancer Institute Hospital of JFCR, Tokyo

40 519

RECRUITING

Pratia Onkologia Katowice, Katowice

25-734

RECRUITING

Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Klinika Hematologii i Transplantacji Szpiku, Kielce

60-185

RECRUITING

Aidport Sp z o o, Skorzewo

03080

RECRUITING

Seoul National University Hospital, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

06200

RECRUITING

Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara

06590

RECRUITING

Ankara University Medical Faculty, Ankara

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY